These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. Kuo T; Wang C; Badakhshan T; Chilukuri S; BenMohamed L Vaccine; 2014 Nov; 32(50):6733-45. PubMed ID: 25446827 [TBL] [Abstract][Full Text] [Related]
27. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Cremer KJ; Mackett M; Wohlenberg C; Notkins AL; Moss B Science; 1985 May; 228(4700):737-40. PubMed ID: 2986288 [TBL] [Abstract][Full Text] [Related]
28. The quest for a herpes simplex virus vaccine: background and recent developments. Hall MJ; Katrak K Vaccine; 1986 Sep; 4(3):138-50. PubMed ID: 3020819 [TBL] [Abstract][Full Text] [Related]
29. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070 [TBL] [Abstract][Full Text] [Related]
30. Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous Herpes simplex virus: implications for a herpes virus vaccine. Scriba M Med Microbiol Immunol; 1978 Nov; 166(1-4):63-9. PubMed ID: 214688 [TBL] [Abstract][Full Text] [Related]
31. Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells. Ghasemi M; Erturk M; Buruk K; Sonmez M Cytotherapy; 2013 Mar; 15(3):352-61. PubMed ID: 23579060 [TBL] [Abstract][Full Text] [Related]
32. Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice. Royer DJ; Carr MM; Chucair-Elliott AJ; Halford WP; Carr DJJ J Virol; 2017 Apr; 91(7):. PubMed ID: 28122977 [TBL] [Abstract][Full Text] [Related]
33. Introduction: objectives of herpes simplex virus vaccines seen from a historical perspective. Roizman B Rev Infect Dis; 1991; 13 Suppl 11():S892-4. PubMed ID: 1664123 [TBL] [Abstract][Full Text] [Related]
35. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403 [TBL] [Abstract][Full Text] [Related]
36. Current status and prospects for development of an HSV vaccine. Johnston C; Koelle DM; Wald A Vaccine; 2014 Mar; 32(14):1553-60. PubMed ID: 24016811 [TBL] [Abstract][Full Text] [Related]
37. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533 [TBL] [Abstract][Full Text] [Related]
39. Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis. Naidu SK; Nabi R; Cheemarla NR; Stanfield BA; Rider PJ; Jambunathan N; Chouljenko VN; Carter R; Del Piero F; Langohr I; Kousoulas KG PLoS One; 2020; 15(2):e0228252. PubMed ID: 32027675 [TBL] [Abstract][Full Text] [Related]